Bristol Myers: failure of glioblastoma study
(CercleFinance.com) - Bristol Myers Squibb announces that CheckMate -548, its phase-3 trial to evaluate the addition of Opdivo (nivolumab) to the current care standards, did not reach its primary endpoint of overall survival of patients.
This study, versus placebo, plus standard of care was conducted on patients suffering from glioblastoma multiforme with methyltransferase (MGMT) promoter methylation after surgical resection of the tumour.
The independent data monitoring committee also informed the pharmaceutical lab that there were no safety concerns observed in patients treated with Opdivo that would justify stopping the study.
Copyright (c) 2020 CercleFinance.com. All rights reserved.